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a b s t r a c t
Proteolytic processing of viral polyproteins is essential for retrovirus infectivity. Retroviral proteases (PR)
become activated during or after assembly of the immature, non-infectious virion. They cleave viral
polyproteins at speciﬁc sites, inducing major structural rearrangements termed maturation. Maturation
converts retroviral enzymes into their functional form, transforms the immature shell into a metastable
state primed for early replication events, and enhances viral entry competence. Not only cleavage at all
PR recognition sites, but also an ordered sequence of cleavages is crucial. Proteolysis is tightly regulated,
but the triggering mechanisms and kinetics and pathway of morphological transitions remain enigmatic.
Here, we outline PR structures and substrate speciﬁcities focusing on HIV PR as a therapeutic target.
We discuss design and clinical success of HIV PR inhibitors, as well as resistance development towards
these drugs. Finally, we summarize data elucidating the role of proteolysis in maturation and highlight
unsolved questions regarding retroviral maturation.
& 2015 Elsevier Inc. All rights reserved.
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Introduction: proteases are essential retroviral enzymes
With genome sizes in the range of 10 kilobases, retroviruses
have to rely on strategies of genetic economy in order to encode
all proteins required for particle formation, replication and spread.
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A possible way to solve this problem, employed by many different
virus groups, is the expression of polyproteins that are subse-
quently proteolytically processed into functional subunits. Beyond
saving space on the genome by using a single set of transcriptional
and translational control elements, this approach provides the
option to alter the functionality of a particular protein in a
controlled manner. Furthermore, it ensures the production of
multiple proteins in deﬁned stoichiometry and their targeting to
speciﬁc sites using a single targeting signal. Retroviruses make use
of this strategy by translating their major structural proteins and
the viral replication enzymes as part of the group speciﬁc antigen
(Gag) or polymerase (Pol) polyprotein entity, respectively.
Together with the envelope (env) open reading frame (ORF), gag
and pol constitute hallmark ORF of all retroviruses (Vogt, 1997).
In a retrovirus-producing cell, viral components assemble into
particles in a process mainly orchestrated by the Gag polyprotein,
which forms spherical or semi-spherical shells encasing the viral
genome. The resulting immature particles are non-infectious,
however. Proteolysis of the polyproteins, accompanied by drastic
rearrangement of virus architecture, is essential to convert these
immature virions into mature, infectious virus (Swanstrom and
Wills, 1997). Early biochemical studies on murine and avian
retroviruses provided evidence for the synthesis and processing of
viral polyproteins (Vogt and Eisenman, 1973; Vogt et al., 1975) and
revealed that the corresponding protease is encoded by the virus itself
(Dittmar and Moelling, 1978; Vogt et al., 1979; von der Helm, 1977;
Yoshinaka and Luftig, 1977). Today, we know that the virus encoded
protease (PR) represents an essential enzyme of all retroviruses.
PR itself is encoded as part of a polyprotein whose production
often requires a ribosomal frameshift event or read-through of a
stop codon. The exact arrangement of the gag, pro and pol ORFs
varies between different retroviruses ((Vogt, 1997); Fig. 1).
Depending on genome structure, PR is encoded either as part of
gag (e.g. Rous sarcoma virus (RSV), a member of the avian sarcoma
and leucosis viruses, ASLV), as part of pol (e.g. human immunode-
ﬁciency virus, HIV-1; murine leukemia virus, MLV), or as a
separate ORF (e.g. Mason-Pﬁzer monkey virus, M-PMV). As a
consequence, PR is either synthesized in equimolar amounts to
Gag, in equimolar amounts to reverse transcriptase (RT) and
integrase (IN), or in lower amounts than the structural proteins,
but higher than the other enzymes.
Retroviral proteases (correctly denominated“retropepsins“
(Barrett et al., 2012)) and their inhibition have been intensively
studied for several decades, and speciﬁc aspects are covered in
several excellent recent reviews, some of which are cited below.
We refer the reader to these reviews for further information and
sincerely apologize to all colleagues whose excellent work could
not be discussed and cited here due to space limitations.
Structure and function of retroviral proteases
Retropepsins undoubtedly represent the most thoroughly stu-
died proteolytic enzymes in the history of science (Barrett et al.,
2012). The last three decades have witnessed an amazing con-
centration of resources and intellectual potential on the study of
these comparatively simple hydrolytic enzymes, leading to an
unprecedented accumulation of information regarding their struc-
ture, enzymology and inhibition. These efforts have been mostly
fueled by the need to develop effective inhibitors of HIV-1 PR as
antiviral drugs. Accordingly, HIV-1 PR is by far the most studied of
all retropepsins. Other enzymes that have been studied in some
detail include the PR of RSV, the prototype alpharetrovirus, of MLV,
the prototype gammaretrovirus, and the PRs of HIV-2 and human
T-cell leukemia virus (HTLV) due to the pathogenicity of the
corresponding viruses. In addition, M-PMV PR has been studied
primarily because of its unusual expression (as a separate ORF
between gag and pol) and because of the unique maturation
pathway of this betaretrovirus (see below). According to its
dominance in the scientiﬁc literature, we will focus our review
mostly on the description of the structure, substrate speciﬁcity and
mechanism of action of HIV-1 PR and will discuss speciﬁc and
divergent features of other retropepsins.
Retropepsins are relatively small aspartic proteases comprised
of two identical monomers of 10–15 kDa each (Fig. 2). As other
enzymes of this class, they display optimal activity on peptide
substrates in vitro under acidic conditions and are poorly active on
model peptides at neutral or higher pH (e.g. Billich et al., 1988;
Darke et al., 1989; Hyland et al., 1991). Three amino acids in the
active site (Asp, Thr/Ser and Gly) form a catalytic triad common to
all aspartic proteases. While the cellular aspartic proteases such as
pepsin or cathepsin D carry two catalytic aspartates within a single
gag-pro
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Fig. 1. PR is expressed as part of retroviral polyproteins. The schemes show the genomic localization of the PR encoding region (dark gray box) in different exemplary
retroviruses. Vertical lines represent cleavage sites of the respective PR; arrows indicate sites of translational read-through (MLV) or frameshift (other viruses) resulting in
expression of Gag–Pro or Gag–Pro–Pol polyproteins, respectively. Canonical Gag domains (MA, CA, NC) are colored light gray. Spacer peptide 1 (SP1) and 2 (SP2) (black boxes)
are localized between the CA and NC domains and between the NC and p6 domains of HIV-1 Gag, respectively. RSV, Rous sarcoma virus, MLV, murine leukemia virus;
M-PMV, Mason-Pﬁzer monkey virus; HIV-1, human immunodeﬁciency virus. DU, dUTPase
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polypeptide, one catalytic aspartate is provided by each mono-
meric subunit in the case of retropepsins (Pearl and Blundell,
1984). In the vicinity of the active site, a hydrogen bond network
called the “ﬁreman's grip” (Pearl and Blundell, 1984) supports the
relative rigidity of the core of these enzymes. A glycine rich “ﬂap”
region forms a dynamic “roof” covering the active cleft of all
retropepsins and plays an important role in substrate recognition
(Fig. 2A). This ﬂexible region consisting of two β-hairpins under-
goes signiﬁcant conformational alterations, changing its topology
between the open, semi-open and closed conformation (Fig. 2A),
depending on the binding of a substrate or inhibitor. PR dimeriza-
tion is mainly mediated by its N- and C-termini (residues 1–4 and
96–99 in the case of HIV-1 PR) intertwining into a four-stranded
antiparallel β-sheet (Fig. 2). The requirement for dimerization to
achieve catalytic competence is an important regulatory feature
contributing to the tight control of proteolytic processing in the
viral replication cycle (see below).
The monomer of RSV PR (124 amino acids; Fig. 2B) is larger
than that of HIV-1, mostly because of two larger surface loops
including the “ﬂap”. These loops are highly dynamic and not well
deﬁned in most X-ray structures of RSV PR. The presence of
Asp–Ser–Gly instead of Asp–Thr–Gly in the active site triplet has
been suggested to lead to a looser folding of the “ﬁreman's grip”
structure and thus to lower dimer stability of RSV PR (Konvalinka
et al., 1995). This lower dimer stability translates into lower
enzymatic activity of RSV PR compared to HIV-1 PR, which may
compensate for the higher PR production since the enzyme is
produced as a component of the Gag polyprotein in this case
(Fig. 1). Exchanging Ser to Thr in the active site of RSV PR resulted
in increased speciﬁc activity of the enzyme and aberrant virion
morphology (Konvalinka et al., 1992; Sedlacek et al., 1993).
M-PMV PR (Fig. 2B) differs in several aspects from the PR of
other retroviruses. It was shown to exist in three forms, differing
in the length of the C-terminus (17 kDa, 13 kDa and 12 kDa), with
both 17 and 13 kDa forms found in viral particles (Pichova, 2013).
The enzyme crystallizes as a monomer rather than in its active,
dimeric form, impeding reﬁnement of its structure by molecular
replacement using either models or known NMR structures
(Veverka et al., 2001). Finally, the structure of the monomer was
solved with the help of players of a multi-level computer game
“Foldit” (Khatib et al., 2011), who generated models useful for the
solution of a crystal structure. Interestingly, the M-PMV PR
structure lacks the dominant interfacial beta-sheet that stabilizes
the dimers of other retropepsins (Fig. 2B, right).
The substrate speciﬁcity of retropepsins is complex. Sequencing
of mature retroviral proteins provided initial information on the
substrate speciﬁcity of the respective PR. Much of the early
information has been obtained by the diligent work of Oroszlan
and co-workers (reviewed e.g. in (Oroszlan and Luftig, 1990)).
Subsequent experiments involving cleavage of peptide libraries
and panels of synthetic peptides by retroviral PRs and the identiﬁca-
tion of cellular protein substrates of these enzymes provided a reﬁned
picture of the substrate speciﬁcity of these enzymes, again revealing a
relaxed speciﬁcity (e.g. Cameron et al., 1992; Grinde et al., 1992;
Konvalinka et al., 1990; Kotler et al., 1988). This result was consistent
with early studies indicating promiscuous cleavage of denatured
protein substrates (Dittmar and Moelling, 1978), while the respective
folded protein was much more resistant, indicating a contribution of
structural accessibility to PR speciﬁcity.
A comprehensive picture of the substrate speciﬁcity of proteo-
lytic enzymes can be provided by proteomic identiﬁcation of
cleavage sites (PICS). This method, introduced by Overall and co-
workers, enables the simultaneous characterization of the cleavage
sites of an endopeptidase by LC-MS analysis of the newly created N-
termini in trypsin-treated cell lysates offered as substrates (Schilling
et al., 2011). Fig. 3 shows results for HIV-1 PR using a peptide library
comprised of 1156 hydrolyzed peptides from the HEK293T pro-
teome (Tykvart et al., 2015). The ﬁgure shows favored residues in
the region from P5 to P50 represented as a heat map (Fig. 3A) or
sequence logo representation (Fig. 3B). The major substrate speci-
ﬁcity signature features of HIV PR involve (i) a preference for Glu in
the P20 position; (ii) a certain preference for large aliphatic and
Fig. 2. Three-dimensional structures of selected retroviral PRs. (A) Crystal structures of HIV-1 PR in three conformations: the apo-form of the HIV-1 PR with ﬂaps in open
conformation (PDB code 3PHV (Lapatto et al., 1989)), HIV-1 PR with ﬂaps in closed conformation (PDB code 4LL3 (Kozisek et al., 2014)) with inhibitor (DRV) bound in the
enzyme active site shown in sticks (with carbon atoms colored green, oxygen atoms red, nitrogens blue and sulfur yellow), HIV-1 PR with ﬂaps in semi-open conformation
(PDB code 1ZTZ (Cigler et al., 2005). Inhibitor bound in the enzyme active site (metallacarborane) is shown in sticks (with carbon atoms colored yellow, boron atoms cyan,
and cobalt atom maroon). In all panels, the ﬂaps (residues 43-58) and dimerization zone (residues 1–4 and 96–99) are highlighted in darker color and active site aspartates
are highlighted in sticks. The ﬁgure was generated using program PyMol (www.pymol.org). (B) Structures of other retroviral PRs: RSV PR with bound inhibitor (PDB code
1BAI), monomeric M-PMV PR (PDB code 3SQF (Khatib et al., 2011)). Figure courtesy of Pavlína Řezáčová.
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aromatic residues in the P1 and P10 positions; and (iii) the rather
unusual preference for Pro in the P10 position. Beta-branched amino
acids are largely excluded from the P1 position, and this has been
used to generate inactivating cleavage site mutations in various
positions of Gag (e.g. Coren et al., 2007; Pettit et al., 2002, 1991;
Wiegers est al., 1998).
Numerous other analyses on the substrate speciﬁcity of HIV-1
and other retroviral PRs revealed a similar picture: there is no
clear pattern in the primary sequence explaining the molecular
recognition of the processing sites or peptide substrates, but a
certain preference for aromatic or large aliphatic amino acid
residues in P1–P10, for Pro in P10 and for large and hydrophobic
amino acids in the P2 and P20 subsites has been generally observed
((Grifﬁths et al., 1992; Richards et al., 1990); compare Fig. 3).
Interestingly, most retropepsins efﬁciently cleave an X-Pro bond
(where X is a large, aromatic amino acid such as Tyr or Phe), a
feature rarely seen in other endopeptidases. It is important to
point out that the substrate preferences in individual pockets of
the enzyme are not independent, and that the nature of the amino
acid residues in the P1–P10 positions inﬂuences the preference of
the enzyme for the residues in neighboring substrate speciﬁcity
pockets (Grifﬁths et al., 1992; Tozser et al., 1997).
The apparent discrepancy between the rather promiscuous
sequence speciﬁcity without clear signature patterns on the one
hand, and the fairly strict requirement of the virus for appro-
priately ordered processing of individual proteins (see below) may
be resolved by the notion that the enzyme seems to preferentially
cleave unfolded linker regions between individual folded domains
while recognizing a common 3D motif shared by all cognate
substrates (Chellappan et al., 2007; Prabu-Jeyabalan et al., 2002).
PR as a target for therapeutic intervention
HIV-1 PR as a prime target for antiretroviral chemotherapy
The importance of HIV-1 as a human pathogen has spurred the
development of speciﬁc small molecule compounds that block
replication by inhibiting various steps in viral replication. Since the
discovery of HIV-1 in 1983, about 30 different antiretroviral drugs
have been introduced into clinical practice. Since inactivation of
HIV-1 PR renders the virus non-infectious (Kohl et al., 1988) and
even partial inhibition of proteolysis severely affects virus replica-
tion (Kaplan et al., 1993), speciﬁc inhibitors of HIV-1 PR are highly
effective antiviral agents. The introduction of PR inhibitors (PIs) in
1995 as part of highly active anti-retroviral therapy (HAART) was a
critical step for decreasing mortality and prolonging life expec-
tancy of HIV-positive patients under treatment. At present, there
are nine HIV PIs approved as antiviral agents by the US Food and
Drug Administration (FDA).
The literature on HIV PIs is very large (the Web of Science
returns over 60,000 search results for “HIV Protease Inhibitor”)
and has been the subject of a number of excellent and thorough
reviews (e.g. Adamson, 2012; Anderson et al., 2009; De Clercq, 2005;
Pokorna et al., 2009; Wlodawer and Erickson, 1993). Within the frame
of this article, we will only brieﬂy introduce the currently approved PIs
and will expand this to some less orthodox approaches towards PI
inhibition that have not been recently reviewed.
All FDA-approved HIV PIs are competitive inhibitors binding to
the enzyme active site. The ﬁrst generation drugs have been
designed as peptidomimetics of the respective processing sub-
strate (Fig. 4). Most of these compounds suffer from poor bioavail-
ability and unwanted side effects. PIs often interfere with lipid
metabolism and trafﬁcking pathways (Barbaro and Iacobellis,
2009; Duvivier et al., 2009; Mallewa et al., 2008). These side
effects are not only medically relevant per se, but can also decrease
the adherance to treatment regimes and thus contribute indirectly
to the evolution of resistance (see below).
Pharmacokinetic properties of PIs can be improved by co-
administration of an inhibitor of cytochrome P450 3A4, the
microsomal enzyme responsible for the metabolism of PI and
other xenobiotics. Interestingly, one of the ﬁrst clinically approved
HIV PIs, ritonavir (RTV), was soon recognized as a potent inhibitor
of cytochrome P450 3A4 and is currently used almost exclusively as
pharmacokinetic boosting agent increasing the plasma concentration
of other PIs (Moyle, 2001). In fact, all other clinically used PIs with the
exception of nelﬁnavir (NFV) are routinely co-administered with a low
dose of RTV as a pharmacokinetic booster.
The ﬁrst generation compounds saquinavir, ritonavir, indinavir
and amprenavir (SQV, RTV, IDV, APV; Fig. 4) were designed to bind
Fig. 3. Heat map (A) and Kullback–Leibler sequence logo representation (B) of substrate speciﬁcity of HIV PR obtained from a PICS experiment (Tykvart et al., 2015). A tryptic
library from HEK293T cell lysates was cleaved by recombinant HIV PR. As a control, the same tryptic library was treated by a catalytically inactive mutant of HIV PR (D25N).
(A) The heat-map illustrates ratios of individual amino acid occurrence at given position compared to overall probability of given amino acid occurrence in the human
proteome. Ratios above 1 (preferred) are shown in green while ratios below 1 (rejected) are shown in red with shading intensity corresponding to the ratio. (B) A Kullback–
Leiber sequence logo was generated from cleaved sequences using the Seq2Logo tool (Thomsen and Nielsen, 2012). Amino acids enriched at a given position are shown on
the positive y-axis and depleted amino acids on the negative y-axis. Height of each letter is proportional to its probability of occurrence at the given position. Amino acids are
color coded to highlight acidic (red), basic (blue) and hydrophobic (black) residues. Five positions each on both sides of the cleavage site (P50–P5) are shown. Figure courtesy
of Michal Svoboda.
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Fig. 4. Inhibitors of HIV PR (A) Chemical structures of FDA approved HIV PI. (B) Binding of DRV to the active site of HIV-1 PR. Hydrogen bonding interactions between DRV
and PR are represented as dotted lines. The ﬁgure was generated using the PDB code 3GGU (Kozisek et al., 2014) and program PyMol (www.pymol.org). Figure courtesy of
Pavlína Řezáčová.
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wild-type HIV-1 PR. Their binding modes share common features:
tight binding to the enzyme is achieved by non-polar van der
Waals interactions of the inhibitor's side-chains. These interac-
tions can be easily disrupted by conservative amino acid mutations
in the vicinity of the binding cleft, thereby promoting rapid
resistance development. Thus, further drug development aimed
at PIs active against HIV-1 PR variants resistant to ﬁrst generation
PIs, as well as at compounds with less side effects and/or increased
oral availability. Examples of second generation PIs are lopinavir
(LPV; (Sham et al., 1998)) and the most recently approved drug
darunavir (DRV; formerly TMC-114, UIC-94017 (Koh et al., 2003)).
An important feature of the latter compound is the bis-
tetrahydrofuranyl moiety by which it differs from the structurally
related PI APV (Fig. 4). This moiety forms crucial hydrogen bond
interactions with the main chain of Asp29 and Asp30 in the PR
binding cleft, mimicking the hydrogen bond network of the
polyprotein substrate of HIV PR (Prabu-Jeyabalan et al., 2000).
The compound ﬁts to the “substrate envelope” within the binding
cleft of HIV-1 PR as proposed by Schiffer et al. (Chellappan et al.,
2007; Prabu-Jeyabalan et al., 2002). This binding mode results in
broad speciﬁcity of the inhibitor towards a variety of highly
mutated, resistant PR species. Several lines of indirect evidence
further suggest that DRV might bind not only to the active site, but
also to a surface pocket in the ﬂaps of the enzyme (Kovalevsky
et al., 2008, 2006), and may thus act by a dual mechanism
(i.e. involving dimerization inhibition in addition to targeting the
active site (Koh et al., 2007)). However, analyses of DRV resistant
virus identiﬁed in patients under prolonged DRV treatment did not
reveal an additional cluster of mutations that would support such
an alternative mode of action (Saskova et al., 2009).
Antiretroviral resistance development
The extremely high replication rate of HIV-1, together with a
lack of proofreading activity of RT, results in rapid accumulation of
random mutations in the viral genome. It has been estimated that
as many as 1010 new virus particles are generated every day
in an untreated patient (Perelson et al., 1996). This high replication
rate together with the low ﬁdelity of the viral RT predicts that
every possible change occurs every day at every position of the
viral genome in a patient with active viral replication (Cofﬁn,
1995). The high population dynamics result in mixed virus
populations (‘quasispecies’) carrying highly diverse PR coding
sequences, and some PI resistance mutations have been observed
in the absence of any previous use of PIs (e.g. (Kozal et al., 1996)).
As a consequence, development of inhibitors requiring multiple
resistance mutations and combination therapy is crucial in
order to raise the genetic barrier to resistance and prevent the
rapid selection of resistant virus variants under therapy. The
emergence of resistance against HIV-1 PIs represents an impress-
ive example of microevolution in the test tube and of evolutionary
plasticity in vivo: this enzyme of 99 amino acids can tolerate
the exchange of 22 residues (i.e. more than one ﬁfth of its
sequence), while still retaining the ability to correctly process its
substrate and support viral replication (Menendez-Arias, 2013;
Rhee et al., 2010).
Resistance can develop against every PI (or any other antiviral
drug) in clinical use, and cross resistance against multiple PIs can
also occur (for a more detailed report on this topic see (Anderson
et al., 2009; Fun et al., 2012; Menendez-Arias, 2013; Rhee et al.,
2010) and references therein). Mutations conferring viral resis-
tance to PIs are divided into three groups: major (primary)
mutations, minor (secondary, compensatory) mutations, and (ter-
tiary) mutations in the processing sites of the Gag and Gag–Pro–
Pol polyproteins (Fig. 5). The major mutations directly affect the
binding cleft of the enzyme and result in decreased binding
afﬁnity of the PI; this often correlates with decreased afﬁnity of
the polyprotein substrate, and these mutations therefore generally
come at a cost for viral replication ﬁtness. Secondary and tertiary
mutations restore ﬁtness by enhancing substrate afﬁnity or turn-
over rates; this can be achieved by alteration of PR (secondary
mutations) or by adaptation of its substrate (tertiary mutations).
Fig. 5. Sites of known primary and secondary resistance-associated mutations in HIV-1 PR. Three dimensional model of the HIV-1 PR structure depicting mutations
associated with resistance to clinically used PI. Backbones of the two monomeric subunits are represented as light blue and red lines, respectively; active site aspartates and
the inhibitor DRV (green) bound to the active site are represented as stick models. Mutated residues found in resistant PR variants are indicated with their Cα atoms (spheres)
and colored red and blue for major (primary) and minor (secondary) mutations, respectively; numbers refer to amino acid positions. The ﬁgure was generated using the
structure of a highly mutated patient derived HIV-1 PR (PDB code 3GGU (Saskova et al., 2009)) and program PyMol (www.pymol.org). Tertiary resistance associated
mutations, i.e. exchanges at PR recognition sites in the substrates, are not included in the ﬁgure. Figure courtesy of Pavlína Řezáčová.
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At least 50 residues of HIV-1 PR have been reported to be prone to
primary or secondary resistance mutations (Menendez-Arias,
2013; Rhee et al., 2010). In addition to amino acid substitutions,
insertions of one to six residues in HIV-1 PR have been reported
that also decrease PI sensitivity (Kozisek et al., 2008b).
Tertiary resistance mutations do not affect PR itself, but alter
amino acid sequences at polyprotein processing sites. These
mutations adapt the substrate to the modiﬁed requirements of
the mutated enzyme's binding cleft (Doyon et al., 1996; Mammano
et al., 1998; Zhang et al., 1997). Nijhuis et al. observed that
mutations in the vicinity of the processing sites can accumulate
even before the occurrence of primary mutations in the PR coding
region. This phenomenon may be important for early resistance
development and may explain HIV-1 therapy failures in the
presence of wild type PR (Nijhuis et al., 2007).
Resistance development is delayed for PIs with a higher genetic
barrier to resistance, i.e. compounds that require multiple muta-
tions in PR for resistance development. An example is DRV, which
has been designed to ﬁt the 3D-space in the binding cleft of HIV-1
PR that represents the minimal volume for the binding of natural
substrates (see above) and to form backbone-backbone hydrogen
bonds difﬁcult to modify by amino acid exchange. A highly
resistant HIV-1 variant recently isolated from a patient under
DRV treatment harbored 22 mutations in the PR coding region
(Kozisek et al., 2012). This PR variant retained only 1.4% of wild-
type enzymatic activity (as quantiﬁed by in vitro analysis using
recombinant PR), but was still able to support viral replication. If
the in vitro processing kinetics correctly reﬂects the situation in
the budding virus, this number would suggest a threshold for PR
activity required for HIV-1 infectivity. One must consider, however,
that alterations in Km may not be relevant at the very high
concentrations (mM range) of enzyme and substrate inside the
budding virion (Konvalinka et al., 1995).
Novel compounds
Development of PI resistance can be overcome by either
increasing blood plasma concentration of the drug or by admin-
istering a compound with a different binding mode to the enzyme
and thus a different resistance proﬁle (Pokorna et al., 2009).
Therefore, academia and pharmaceutical industry continue to
search for novel, highly active compounds with improved resis-
tance proﬁles, better pharmacokinetic properties, and fewer
adverse effects. This can be achieved by identifying chemical
scaffolds with different binding modes. One strategy is to design
irreversible inhibitors of HIV-1 PR, which react with the active site
aspartate residues and yield an inactive covalent adduct. The only
mutation that could plausibly cause resistance against such a small
irreversible inhibitor would be a mutation of the active site Asp,
which in turn would inactivate the enzyme and thereby block viral
replication. Thus, irreversible inhibitors would be expected to be
less sensitive to PR mutations that decrease the binding afﬁnity of
the inhibitor. Many attempts have been made to develop an
irreversible inhibitor that covalently binds to the catalytic aspar-
tates. However, there has been little progress since the identiﬁca-
tion of the initial irreversible peptidomimetic inhibitors ((Ro et al.,
1998); reviewed in (Schimer and Konvalinka, 2014)). Irreversible
inhibitors available to date are characterized by insufﬁcient
selectivity and speciﬁcity for HIV-1 PR and a short half-life in vivo.
Blocking dimerization of PR is another potential target for
alternative PIs, since this process is indispensable for proteolytic
activity. Indeed, small molecules interfering with HIV-1 PR dimer-
ization display inhibitory potential (Zhang et al., 1991), and were
reported to be active against PR variants bearing resistance-
causing mutations (Shultz et al., 2004). Short peptides that mimic
the C- and N-terminal parts of PR yielded PIs with micromolar
potency (Zhang et al., 1991). These peptide sequences have been
connected with various non-peptidic linkers (Zutshi and
Chmielewski, 2000), increasing antiviral potency (Davis et al.,
2006; Vidu et al., 2010). The active site-directed compound DRV
(see above) has been suggested to also disrupt PR dimerization,
and thus to target the same enzyme by two independent
approaches (Koh et al., 2011,, 2007).
Apart from the dimerization domain, there are other structural
features that could be a target for drug development, including the
movable “ﬂaps”. When the enzyme switches from the open state
to the closed (substrate-bound) state (Fig. 2), the ﬂap hinge region
(residues 37–42) presents a small hydrophobic binding site. This
site could be targeted by small molecules, thereby preserving the
closed state and preventing PR from binding its substrate. Small
chemical building blocks such as 2-methylcyclohexanol or indole-
6-carboxylic acid have shown some promise and may provide a
starting scaffold for further development (Perryman et al., 2010).
Other compounds, such as beta-lactams, bind to areas of the ﬂap
region closer to the active site (Sperka et al., 2005). Cigler et al
(2005) targeted the ﬂap region with metallocarboranes. These
compounds retained high inhibitory activity even against highly
mutated PR that displayed low susceptibility to currently used PIs
(Kozisek et al., 2008a; Rezacova et al., 2009). Metallocarboranes,
with their unique binding mode and a good cross-resistance
proﬁle, are an interesting scaffold that already proved its potential
for the design of inhibitors of other biologically relevant enzymes
(carbonic anhydrase IX, (Brynda et al., 2013)).
Finally, there is also surprising structural and chemical diver-
sity among the more “conventional” compounds targeting the
active site of HIV PR. The PR substrate binding cleft can accom-
modate fullerenes (Friedman et al., 1998), large ruthenium clusters
(Wong et al., 2006), seven-membered cyclic ureas (Lam et al.,
1994), compounds with peptide bonds replaced by pyrrolinones
(reviewed in (Smith et al., 2011)), β-hydroxy γ-lactams (Wu et al.,
2012), sulfoximines (Lu and Vince, 2007) or dibenzodiazepine
derivatives (Schimer et al., 2012). Clearly, HIV-1 PR will continue
to be an exciting target for antiviral drug development.
Role of PR in the retroviral replication cycle
Immature and mature retroviral particles: same, but different
Retroviral Gag and Gag–Pro–Pol polyproteins are processed
into functional subdomains during maturation, accompanied by
dramatic structural rearrangements within the virion. Canonical
Gag domains are from N- to C-terminus, MA (matrix) lining the
viral envelope, CA (capsid) forming the mature capsid structure
and NC (nucleocapsid) packaging and condensing the viral geno-
mic RNA ((Vogt, 1997); see Fig. 1). In addition, all retroviral Gag
polyproteins carry so-called “late motifs” recruiting the cellular
endosomal sorting complex required for transport (ESCRT)
machinery and thus facilitating virus release (Bieniasz, 2009;
Votteler and Sundquist, 2013). Besides that, Gag polyproteins from
different retroviruses may contain further subunits and in some
cases short spacer peptides that are important for the regulation of
the maturation process (see below), but without known function
in the mature virus ((Vogt, 1997), see Fig. 1). The morphology of
mature virions varies between different retroviruses, but imma-
ture and mature particles can be clearly distinguished by their
appearance in electron micrographs for every retrovirus (Fig. 6;
reviewed in (Swanstrom and Wills, 1997)).
Immature particles are characterized by a spherical or semi-
spherical shell of Gag polyproteins, in which MA lines the lipid
envelope, CA forms important protein–protein lattice contacts and
NC, bound to the viral genome, extends towards the center of the
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particle. Mature particles, in contrast, contain a condensed nucleo-
protein core surrounded by a spherical, tubular or conical capsid
(Swanstrom and Wills, 1997). CA domain hexamers are the basic
elements of both the immature and the mature lattice. Never-
theless, the architecture of the immature and mature lattices of a
given retrovirus differ signiﬁcantly; this is characterized in the
highest structural detail for HIV-1, but also holds true for other
retroviruses. In the nascent HIV-1 bud, curvature is attained by
small irregular defects in the Gag lattice. The released immature
Gag shell comprises a large gap (Carlson et al., 2008; Wright et al.,
2007), presumably derived from the action of ESCRT components
closing the viral bud and facilitating virus release. In contrast,
mature retroviral capsids are closed fullerene-type structures
where curvature is accomplished by the introduction of CA
pentamers into the hexameric lattice (Ganser et al., 1999; Li
et al., 2000). The structure of the immature and mature hexamer
itself also differs substantially, and there is little overlap between
CA intermolecular contact surfaces used for immature and mature
hexamer formation (Bharat et al., 2012). Recent high resolution
cryo electron-tomography studies revealed further differences
between retroviruses in the immature lattice: M-PMV and HIV-1
both exhibit a similar lattice architecture and almost identical
position of the CA C-terminal domain, while the CA N-terminal
domains show signiﬁcantly different contacts, attesting to the
enormous plasticity of the CA protein (Bharat et al., 2012; Schur
et al., 2014).
Regulation of proteolytic maturation: it is all about control
It is evident that the complex process of retrovirus maturation
has to be tightly regulated in space and time. Initiation and
progress of polyprotein cleavage have to be closely coordinated
with virus assembly and budding. Furthermore, individual struc-
tural components should be released in a deﬁned sequence to
allow for complex structural rearrangements within the conﬁned
environment of a 125 nm particle. How this precise control and
regulation is accomplished is largely unclear, however. Important
open questions concern the nature of the triggering event and its
timing with respect to virus formation. Likewise, the kinetics of
polyprotein processing in the context of the assembled virus is
unknown, and the dynamics and pathway of structural rearrange-
ments have yet to be analyzed.
For retroviruses assembling at the plasma membrane, proteo-
lysis should ideally be delayed until the structural polyproteins
reach the assembly site and are conﬁned in the nascent particle.
Several lines of evidence suggest that proteolysis indeed only
occurs concomitant with or shortly after virion release
(i) morphologically immature particles are detected in the vicinity
of virus-producing cells in electron micrographs; (ii) nascent HIV-
1 buds at the plasma membrane display an immature Gag lattice
structure (Carlson et al., 2008); (iii) polyprotein subunits appear to
be present in particles in constant, roughly equimolar amounts. It
is currently not known, how the delay of polyprotein processing is
accomplished. In most retroviruses, Gag:PR stoichiometry is regu-
lated by expression through stop-codon suppression or transla-
tional frameshift from the Gag reading frame (see Fig. 1). Since
these events occur only in a fraction of translation events,
approximately 20 molecules of Gag are synthesized per PR mono-
mer. Lower expression of PR compared to Gag is not an absolute
requirement, however: genomes of ASLVs encode PR as a domain
of Gag and thus synthesize the enzyme in equimolar amounts
with the polyprotein, indicating that mechanisms other than
intracellular concentration of PR subdomains can be important
to prevent premature proteolysis.
An important regulatory mechanism used by all retroviruses is
the expression of a catalytically inactive PR monomer; PR domains
within the initially translated precursors thus need to dimerize to
form an active enzyme. In the context of the polyprotein, dimers of
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Fig. 6. Proteolytic maturation of retroviruses induces morphological changes. (A) Rearrangements of Gag domains accompanying HIV-1 maturation. The ﬁgure shows thin-
section electron micrographs of immature and mature HIV-1 and sketches indicating the position of Gag domains. (B, C) Morphologies of exemplary immature and mature
retrovirus particles visualized by thin-section EM (B; M-PMV) or cryo-electron tomography (C; HIV-1, MLV). Images courtesy of Michaela Rumlova (M-PMV), John Briggs
(HIV-1; panel C) and Alan Rein (MLV). Scale bars: 50 nm.
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the HIV-1 PR region are less stable and adopt an inactive
conformation for most of the time (Agniswamy et al., 2012;
Huang et al., 2011; Louis et al., 1999; Tang et al., 2008), As a
consequence, they display low enzymatic activity and signiﬁcantly
decreased sensitivity towards PIs targeting the mature enzyme
(Davis et al., 2012; Pettit et al., 2004). Initial processing appears to
occur upstream of the N-terminus of PR (SP1-NC and TF-p6pol
cleavage sites) by an intramolecular mechanism, resulting in
enhancement of enzymatic activity (Pettit et al., 2004,, 2003,,
2005). Due to its dependence on precursor dimerization, PR
activity is controlled by intracellular polyprotein concentration,
and PR may thus be activated by concentrating PR-monomer
containing polyproteins upon virus assembly. Particular spatial
arrangements induced by lattice formation, as well as interaction
with lipids or nucleic acids may also play a role in PR activation
(see below). Accordingly, retroviruses engineered to encode two
monomers of PR joined by a ﬂexible linker display enhanced,
premature Gag processing and loss of virus formation and infec-
tivity (Burstein et al., 1991; Krausslich, 1991). Premature proces-
sing can also be induced by overexpression of PR or Gag–Pro–Pol
(e.g.(Mergener et al., 1992; Park and Morrow, 1991)), by activating
mutations in PR (e.g. (Xiang et al., 1997)) or – in the case of HIV-1 –
by addition of certain non-nucleosidic RT inhibitors, which pro-
mote Gag–Pro–Pol dimerization by stabilizing intermolecular
interactions between RT domains (Figueiredo et al., 2006).
Dimer formation is likely not the only trigger mechanism,
however. Some HIV-1 variants de-targeted from the plasma
membrane by large deletions in the MA domain assemble into
apparently intact particles at intracellular membranes, but these
particles remain morphologically immature (Facke et al., 1993;
Gallina et al., 1994; Reil et al., 1998). An important role for the site
of retrovirus assembly on maturation can be deduced from experi-
ments with murine intracisternal A-type particles (IAP), a group of
endogenous retroviruses that normally bud at the endoplasmatic
reticulum. Only immature particles are observed in IAP-producing
cells, although the IAP PR is catalytically competent (Strisovsky et al.,
2002). Re-targeting IAP assembly to the plasma membrane by
modiﬁcation of targeting signals within Gag led to efﬁcient Gag
processing by IAP PR (Welker et al., 1997). These observations suggest
that speciﬁc feature(s) encountered at the plasma membrane (or a
subset of cellular membranes) may serve as additional trigger to
initiate proteolysis. This hypothesis is further strengthened by the
maturation pathway of D-type retroviruses like M-PMV, which
assemble complete immature capsids in the cytoplasm, whereas
polyprotein processing and morphological maturation are delayed
until their budding from the plasma membrane.
The clear distinction between immature assembly and matura-
tion in M-PMV could be exploited to investigate potential trigger-
ing mechanisms. Parker and Hunter (2001) reported that
proteolysis of cell-free immature M-PMV capsids is induced upon
addition of reducing agents, suggesting that a speciﬁc intracellular
redox environment might serve as a trigger for maturation.
Similarly, treatment with a mild oxidizing agent has been shown
to result in reversible inhibition of MLV PR (Campbell et al., 2002).
Reversible oxidation of cysteine residues in the PR dimer interface
has also been proposed to regulate HIV-1 PR activity (Davis et al.,
1999), in particular with respect to the initial intramolecular
cleavage event in Gag–Pro–Pol (Daniels et al., 2010). Whether
redox regulation of PR indeed represents a key maturation trigger
in the retroviral life cycle and/or whether other factors e.g. speciﬁc
cellular proteins or lipids may play a role remains to be deter-
mined. Since retroviral PRs display maximal activity at lower than
neutral pH it is intuitive to propose that a (transient) decrease in
local pH may also contribute to PR activation. It should be noted in
this respect, however, that the optimal conditions for full Gag and
Gag–Pro–Pol processing in the natural context are not known.
Whereas the pH optimum of PR using synthetic peptide substrates
or denatured proteins in vitro is in the acidic range (e.g. (Billich
et al., 1988; Darke et al., 1989; Hyland et al., 1991), the exact pH-
activity proﬁle varies for different peptide substrates and condi-
tions. The presentation of cleavage sites in the context of a folded
protein further inﬂuences the pH-sensitivity of the reaction. While
cleavage at the CA-SP1 processing site in HIV-1 Gag was found to
be signiﬁcantly enhanced by acidiﬁcation (Pettit et al., 1994),
cleavage at MA–CA using either full length Gag (Pettit et al.,
1994) or an engineered protein substrate (Lee et al., 2012)
occurred with similar efﬁciency at pH 6.0 or 7.0. How alterations
in pH would affect initiation and completion of proteolytic
processing in the full viral context is thus difﬁcult to predict. To
date, experimental evidence for a role of the local and potentially
transient pH environment in PR activation is lacking. The detection
of punctuate HIV-1 Gag assemblies upon labeling of the protein
with the pH-sensitive ﬂuorophore pHluorin (Jouvenet et al., 2008)
indicates a local pH of 6.0 or higher at many membrane-associated
Gag assemblies in steady-state.
Role of individual cleavage sites and the functional contribution
of spacer peptides
As outlined above, CA hexamers form the central core of the
immature and the mature lattice, but contact surfaces involved
differ greatly. The inter-hexamer distance is smaller in the imma-
ture than in the mature lattice, indicating that the immature
lattice is more tightly packed (reviewed in (Briggs and
Krausslich, 2011; Ganser-Pornillos et al., 2012)). Furthermore, only
about 50% of CA molecules packaged into the virus as part of the
polyproteins are required for formation of the mature cone
(Lanman et al., 2004). While the pathway of morphological
maturation is currently unknown, these ﬁndings have been taken
as evidence that maturation does not involve condensation from a
spherical shell to a conical core, but rather involves dissociation of
the immature lattice followed by reassembly of the mature capsid.
Such major rearrangements occurring within the conﬁned space of
a virus particle, with Gag subunits present at mM concentration,
obviously require precise organization.
Many lines of evidence from biochemical and virological
studies indicate that retroviral proteolysis is indeed tightly regu-
lated, and that this regulation occurs through sequential cleavage
at individual sites within the Gag polyprotein (Fig. 7). Amino acid
sequences at the different PR recognition sites vary, and kinetic
parameters determined in vitro using PR and synthetic peptides
differ greatly between individual sites (reviewed in (Tozser and
Oroszlan, 2003)). These differences are reﬂected in different
cleavage rates at individual sites when Gag or Gag–Pro–Pol are
used as substrates in vitro (Pettit et al., 2004,, 2002,, 2005,, 1994). A
distinct sequence of cleavages is also followed in the viral context,
as indicated by characteristic patterns of intermediate cleavage
products detected in cell lysates, and in virus particles upon partial
inhibition of PR with suboptimal PI concentrations (Kaplan et al.,
1993). Consistently, blocking cleavage at a particular site in Gag by
mutagenesis can also affect processing at another site.
Mutational studies from many labs showed that complete
cleavage of retroviral Gag at multiple sites is essential for success-
ful maturation. In most cases, blocking processing by muta-
genesis at a single site severely reduced or abolished infectivity
(e.g. (Coren et al., 2007; Oshima et al., 2004; Wiegers et al., 1998)).
Furthermore, not only complete inhibition, but also reduction of
cleavage efﬁciency at an individual site can be detrimental. In the
case of HIV-1 it has been demonstrated that partially processed
intermediates, in particular the slowly cleaved late intermediate
CA-SP1, can exert a strong dominant-negative effect on infectivity
(Checkley et al., 2010; Lee et al., 2009; Muller et al., 2009). This is
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in accordance with the fact that PI concentrations yielding only a
modest inhibition of Gag cleavage affect HIV-1 morphogenesis and
result in signiﬁcant inhibition of viral infectivity (Kaplan et al.,
1993).
In the case of HIV-1 Gag, data from numerous biochemical,
mutational and structural studies can be summarized into a model
of the maturation process (Fig. 7B). Based on the information on
processing kinetics at different sites, cleavages within Gag can be
divided into three categories: (i) initial cleavage at the SP1-NC
boundary separates the RNA-bound NC region from the MA–CA
lattice; (ii) subsequent cleavages separate the CA-lattice from the
membrane associated MA layer and free the NC region from the p6
domain; (iii) the ﬁnal processing steps cleave the spacer peptides
SP1 and SP2 from their N-terminal fusion partners CA and NC,
respectively. These late events, in particular cleavage of the SP1
peptide, play a crucial regulatory role in morphological matura-
tion. In the case of the genetically and morphologically distinct
viruses HIV-1, RSV and M-PMV, the C-terminal region of CA and
the adjacent spacer peptide or a spacer-like region of CA, respec-
tively, represent a keystone of the immature hexameric lattice;
mutations or deletions in this region affect immature particle
formation (e.g. Accola et al., 1998; Keller et al., 2008; Krausslich
et al., 1995). Early cryo-EM analyses of immature HIV-1 (Briggs
et al., 2009; Wright et al., 2007) suggested that this region forms a
6-helix bundle, supporting the previous proposition that this
region exhibits helical propensity (Accola et al., 1998). Consistent
with the helix bundle model, a synthetic peptide covering SP1 and
adjacent amino acids can fold into an alpha-helix at high concen-
trations similar to those present within the virion (Datta et al.,
2011). A similar structure has also been suggested for RSV and M-
PMV (Bush et al., 2014; de Marco et al., 2010a). While MLV does
not encode a spacer peptide directly downstream of CA, a
sequence at the C-terminus of MLV CA was shown to be important
for particle assembly and has been proposed to form a ‘charged
assembly helix’ (Cheslock et al., 2003; Oshima et al., 2004). A very
recent high resolution cryo-EM model of immature HIV-1 parti-
cles, while still not allowing unequivocal assignment of side chains
in the SP1 region, indicates that the respective regions from six
Gag molecules form a hollow bundle transcending from the CA
hexamer to the interior nucleocapsid layer (Schur et al., 2014).
Cleavage both upstream and downstream of the CA-SP1 mod-
ule is required to initiate resolution of the immature lattice
(de Marco et al., 2010b). However, inhibition of subsequent
processing between CA and SP1 prevents dissociation of the CA
layer (Wiegers et al., 1998) and apparently locks the lattice in an
unproductive, partially disordered state (de Marco et al., 2010b;
Keller et al., 2013), lending further support to the disassembly-
assembly model of capsid formation. This phenotype is not only
observed upon mutation of the CA-SP1 processing site, but is also
the explanation for the anti-HIV-1 effect of betulinic acid deriva-
tives (e.g. bevirimat; (Li et al., 2003)) that speciﬁcally block PR
cleavage at this site through interaction with the Gag substrate
(Adamson, 2012,, 2009).
The role of the second spacer peptide in HIV-1 Gag is less
clearly deﬁned. Mutational analyses in the Gag C-terminal region
revealed that the NC-SP2 processing step is dispensable for
efﬁcient virus replication in tissue culture, while inhibiting both
cleavages in the NC-SP2-p6 region severely impaired virus viabi-
lity (Coren et al., 2007). More detailed structural analyses of virus
mutants indicated that not the presence of the spacer peptide
itself, but possibly the proper kinetics of cleavages in this region is
relevant (de Marco et al., 2012). This interpretation is in agreement
with the observation that mutations in the NC-SP2 region are
characteristically observed as tertiary resistance mutations restor-
ing ﬁtness to HIV-1 variants carrying resistance mutations in PR,
which affect the catalytic activity of the enzyme (reviewed in
(Clavel and Mammano, 2010; Fun et al., 2012)). Furthermore,
NC-SP2-p6, NC-SP2 and NC display different abilities to condense
nucleic acid ((Mirambeau et al., 2010) and references therein)
suggesting that successive processing steps in this region regulate
the dynamics of nucleocapsid core formation. Thus, in the case of
HIV-1, the spacer peptides may be proposed to control the process
of morphological maturation by coordinating nucleocapsid con-
densation with assembly of the surrounding conical capsid.
Dynamics and pathway of proteolytic maturation
HIV-1 proteolytic maturation presumably involves only the
viral PR and its substrates Gag and Gag–Pro–Pol in the relatively
deﬁned environment of the virus particle. Nevertheless, the
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Fig. 7. Sequential steps of HIV-1 maturation. (A) PR cleavage sites in HIV-1 Gag and Pol,. Sizes of arrowheads indicate relative rates of cleavage determined in vitro. TF,
transframe peptide. (B) Model for HIV-1 morphological maturation mediated by sequential cleavage of Gag. (i) Initial processing separates NC-SP2-p6 from the MA–CA lattice
and allows initial nucleoprotein condensation. (ii) Cleavage between NC-SP2 and p6 promotes further nucleoprotein condensation. Processing at the MA–CA cleavage site
releases CA from the membrane bound MA layer and induces resolution of the ordered immature lattice. (iii) Cleavage of the spacer peptides from CA and NC results in full
nucleocapsid condensation and dissociation of the CA layer. (iv) Fully processed CA protein forms a mature capsid surrounding the condensed nucleoprotein complex.
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reaction entails at least 66 distinct substrates, intermediates or
products, and numerous competing intermolecular interactions
occurring simultaneously (Konnyu et al., 2013). Furthermore, the
arrangement of the substrates in a tightly packed multimeric
lattice is likely to impose additional constraints that cannot be
mimicked using puriﬁed proteins in vitro. Dynamics of retroviral
processing are difﬁcult to investigate due to the fact that virus
formation in tissue culture occurs in an asynchronous manner.
Individual cells in a population infected at the same time will enter
the state of virus production at different time points, and indivi-
dual HIV-1 particles at the plasma membrane of a single cell
assemble in an asynchronous manner over a time of several hours
(Ivanchenko et al., 2009; Jouvenet et al., 2008). Accordingly,
biochemical ensemble measurements or electron micrographs
capture a mixture of particles at various stages of assembly and
maturation, precluding the analysis of individual stages.
Therefore, the simple question ‘how long does retroviral
maturation take?’ is still unanswered. Dale et al. (2011) proposed
that HIV-1 Gag proteolysis, in the context of virus transmission
between T-cells through ‘virological synapses’, occurs only
after endosomal uptake of the virus into the new host cell and
proceeds slowly over a period of several hours. However, this
interpretation is inconsistent with the fact that morphologically
mature particles, but not recognizable maturation intermediates,
are easily detected by EM in the vicinity of virus producing cells.
Furthermore, mature virions are even observed in the narrow
space between two synapse-forming T-cells (e.g. Jolly et al., 2011;
Martin et al., 2010).
In the case of M-PMV, the clear distinction between assembly
and maturation allowed studying the kinetics of intravirion Gag
processing in vitro. This analysis yielded a half time of roughly
15 min for initial cleavage, but incomplete generation of mature
products (Parker and Hunter, 2001). While this approach is not
feasible for other types of retroviruses, triggering HIV-1 maturation
in vitro can be achieved by preparation of virions in the presence of
a PI followed by rapid inhibitor removal (“inhibitor wash-out”).
Wash-out of PIs with high off-rates (koff, i.e. high velocity constants
of the dissociation of the PR–PI complex) yields virions carrying
nearly fully cleaved Gag (Mattei et al., 2014). Processing is still
limited by the inhibitor off-rate even under optimized conditions,
however. Consequently, infectivity cannot be recovered and parti-
cles displayed disturbed Pol processing and aberrant morphology
(Mattei et al., 2014). To address this problem, we have recently
developed a photocleavable HIV-1 PR inhibitor that allows rapid
activation of the enzyme by UV illumination (Schimer et al., 2015).
Use of this novel tool resulted in more rapid in situ Gag processing:
we observed a half-time of 20–30 min for mature CA formation,
roughly consistent with a mathematical model for HIV-1 matura-
tion (Konnyu et al., 2013). At the current state this represents only
an upper limit of the time frame, however, and more detailed
analyses will be required to unravel the dynamics of HIV-1
maturation.
Asynchronicity of virus formation also impedes the character-
ization of the nature and timing of structural changes involved in
morphological maturation. It is generally assumed that Gag
proteolysis and morphological maturation coincide, but this is
not formally proven. As outlined above, the architecture of
immature and mature HIV-1 particles suggest that maturation
involves dissociation of the immature lattice followed by assembly
of the mature core. Models for the stepwise process relied mainly
on the investigation of viruses partially inhibited for processing by
mutation at individual PR recognition sites or inhibitor treatment
(e.g. de Marco et al., 2010a,, 2012,, 2010b; Keller et al., 2011,, 2013)),
whereas structural information on bona ﬁde maturation inter-
mediates is lacking. Structural data on HIV-1 particles with
unclosed capsid structures (Yu et al., 2013) and of particles
showing neither mature nor immature morphology that were
detected in the vicinity of virus-producing cells (Woodward et al.,
2015) have been taken as evidence that mature capsid formation
occurs through growth of curled CA sheets. Unambiguous inter-
pretation of the latter analyses is hampered by the fact that the
history and future of individual particles cannot be deduced from
still images, however, preventing clear distinction between pro-
ductive maturation intermediates and dead end products.
Recently, an alternative model for morphological maturation
was derived from analysis of assemblies observed in fortuitously
occurring large membranous structures comprising Gag layers and
multiple capsid-like structures (Frank et al., 2015). Based on these
structures, the authors proposed that morphological maturation
does not involve dissociation, but rather a gradual transition of the
immature CA layer to a sheet evolving into a conical capsid. How
the analyzed assemblies relate to intermediates of productive
maturation of individual particles is unclear, however.
Role of proteolysis for viral infectivity
Proteolytic processing of retroviral polyproteins is critical for
infectivity for several reasons. First, the viral enzymes PR, RT and
IN are synthesized as part of polyprotein precursors and need to be
converted into the mature form for full enzymatic activity. Second,
the change in virus architecture is required to transform the
comparatively stable Gag shell into a metastable state ready for
controlled release of the genomic information in a newly infected
target cell. For several retroviruses, the immature Gag shell has
been shown to be resistant towards removal of the lipid envelope
by detergent treatment whereas the mature capsid of many
retroviruses, including HIV-1, rapidly dissociates under these
conditions (e.g. Oshima et al., 2004; Park and Morrow, 1993;
Stewart et al., 1990). These observations are in agreement with
the assignment of the two structures as stable ‘production mode’
and metastable ‘infection mode’. Besides being ready for uncoat-
ing, the mature retroviral capsid also seems to serve important
functions in the early replication phase, and recent studies have
indicated that the HIV-1 capsid or a capsid-derived structure may
remain intact during reverse transcription and possibly even
during transport of the preintegration complex into the host cell
nucleus, at least in some host cell types (Arhel, 2010 and
references therein; Peng et al., 2014). These ﬁndings are consistent
with mutations in the CA domain of Gag exhibiting a phenotype in
early replication and with the observation that various host factors
affecting early HIV-1 replication exert their function by binding to
the capsid or a capsid-derived structure ((Hilditch and Towers,
2014; Matreyek and Engelman, 2013) and references therein).
Finally, proteolytic maturation can increase retrovirus entry
efﬁciency. In the case of MLV and M-PMV, this effect is accom-
plished by PR-catalyzed removal of a C-terminal peptide from the
transmembrane glycoproteins in the viral envelope. Occurring late
in virus formation, this processing step enhances the fusogenicity
of the respective Env protein (Brody et al., 1994; Rein et al., 1994).
Correlation between maturation and entry efﬁciency was also
observed for HIV-1 (Murakami et al., 2004; Wyma et al., 2004),
although the Env protein of this virus is not a substrate for PR. Two
– not mutually exclusive – explanations have been put forward
based on virological, biophysical and imaging analyses. First,
immature HIV-1 particles display signiﬁcantly higher mechanical
stiffness than mature particles as determined by atomic force
microscopy (Kol et al., 2007), consistent with the tightly packed
Gag lattice underlying the viral envelope being converted into a
more loosely connected matrix layer. The increased ﬂexibility of
the mature particle may result in a lower energy barrier for lipid
envelope deformations that need to occur during the membrane
fusion process. Second, Gag processing status appears to be
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correlated to the viral Env protein. Truncation of the long Env
cytoplasmatic tail (CT) relieves the fusion defect of immature HIV-
1 particles, suggesting that immature Gag-EnvCT interactions
hinder the fusion process (Murakami et al., 2004; Wyma et al.,
2004).
Recently developed super-resolution ﬂuorescence microscopy
(SR-FM) methods provided an opportunity to study the distribu-
tion of Env molecules on a large number of individual particles and
correlate this to virus maturation status and infectivity (Chojnacki
et al., 2012). Whereas other enveloped viruses often carry a
densely packed array of viral glycoproteins on their surface, only
a sparse number of Env trimer spikes have been detected on the
surface of HIV-1 (Chertova et al., 2006; Zhu et al., 2006). SR-FM
analyses revealed that Env molecules on the surface of most
immature particles are distributed into multiple clusters, whereas
mature viruses are characterized by a single Env cluster, and this
was dependent on the Env CT (Chojnacki et al., 2012). These
observations support a model proposing constrained lateral move-
ment of Env molecules embedded in a tightly packed Gag lattice.
Resolution of this lattice by Gag cleavage would allow Env
molecules to diffuse and associate based on interactions in the
CT region, which in turn may result in enhanced fusion compe-
tence (Chojnacki et al., 2012). An ‘inside-out signaling’ mechanism
translating proteolytic maturation of the inner virus structure to
changes on the viral surface could ensure that only those viruses
whose cores have converted to ‘infection mode’ will actually enter
the host cell cytoplasm.
Conclusion: unsolved mysteries
About forty years of intense research have gone by since
retroviral polyproteins were ﬁrst identiﬁed (Vogt and Eisenman,
1973) and virus-encoded proteases were found to be key replica-
tion enzymes of retroviruses (von der Helm, 1977). Nevertheless, a
number of very basic questions regarding the viral maturation
process remain unanswered to date. As outlined above, these
questions concern mainly the nature and timing of the triggering
event for PR activation and the dynamics and pathway of mor-
phological maturation.
Since the main obstacle for answering these questions is the
asynchronous process of virus formation in tissue culture, addres-
sing these issues will require (i) experimental systems allowing
direct visualization of PR activation or Gag proteolysis at individual
assembly sites or within individual virions and/or (ii) methods for a
precisely triggered onset of proteolysis in bulk samples. Precise
triggering of the onset of maturation, e.g. by use of a photolabile
HIV-1 PR inhibitor, would not only allow to investigate the precise
time course of polyprotein processing. In conjunction with a – not
yet available – live-cell readout for Gag processing, this might
eventually also enable the investigation of the temporal correlation
between the already well characterized Gag assembly process
(Baumgartel et al., 2012; Jouvenet et al., 2011) and proteolysis. Such
systems would further enable us to investigate the nature and role
of potential triggers for PR activation. Finally, combining rapid
induction of proteolysis with new developments in SR-FM permit-
ting the resolution of transitions in virion architecture, and with
advanced cryo-electron tomography providing sub-nanometer
resolution, may eventually clearly deﬁne structural intermediates
and elucidate the pathway of HIV-1 maturation.
Experimental systems for an inducible activation of PRs in situ
and the continuous development of ﬂuorescent labeling and
readout methods, as well as impressive progress in the ﬁelds of
imaging and image analysis, promise to provide us with suitable
tools for visualization of events within individual virions or at
individual assembly sites in the near future. Ultimately, this might
allow us to directly observe the complex and fascinating process of
infectious retrovirus formation.
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